Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategy.
Paul Maroselli, Joseph Ciccolini(Centre de Recherche en Cancérologie de Marseille), Régis Costello(Inserm), Geoffroy Venton(Inserm), Julien Colle(Inserm), Raphaëlle Fanciullino(Inserm), Pauline Rocher(Assistance Publique Hôpitaux de Marseille), Laure Farnault(Aix-Marseille Université)
Cited by 2
Related Papers
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
|Blood|2021|157
Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx
|Bulletin du Cancer|2018|108
Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors
|Blood Cancer Journal|2016|74
High incidence of atrial fibrillation in patients treated with ibrutinib
|Open Heart|2019|72